 Freeline Therapeutics Holdings plc NASDAQ: FRLN announced the presentation of safety and initial efficacy data from the first cohort of the Phase 12 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vgkg. 